Last $30.97 USD
Change Today +0.22 / 0.72%
Volume 147.6K
BRLI On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 12:16 PM 07/25/14 All times are local (Market data is delayed by at least 15 minutes).

bio-reference labs inc (BRLI) Snapshot

Open
$30.50
Previous Close
$30.75
Day High
$31.10
Day Low
$30.50
52 Week High
11/26/13 - $37.97
52 Week Low
01/6/14 - $24.13
Market Cap
858.7M
Average Volume 10 Days
150.8K
EPS TTM
$1.41
Shares Outstanding
27.7M
EX-Date
--
P/E TM
22.0x
Dividend
--
Dividend Yield
--
Current Stock Chart for BIO-REFERENCE LABS INC (BRLI)

bio-reference labs inc (BRLI) Related Bloomberg News

View More Bloomberg News

bio-reference labs inc (BRLI) Related Businessweek News

No Related Businessweek News Found

bio-reference labs inc (BRLI) Details

Bio-Reference Laboratories, Inc. provides clinical laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases in New Jersey, New York, Maryland, Massachusetts, Texas, and Ohio. The company offers chemical diagnostic tests, such as blood and urine analysis; blood chemistry; hematology services; serology; radio-immuno analysis; toxicology, including drug screening; pap smears; tissue pathology comprising biopsies; and other tissue analysis, as well as cancer cytogenetic testing, genetic testing, and cytology testing services. It focuses on esoteric testing, molecular diagnostics, anatomical pathology, genetics, women’s health, and correctional health care services. The company also operates a clinical knowledge management service unit, which uses customer data from laboratory results, pharmaceutical data, claims data, and other data sources to provide administrative and clinical decision support systems; and a Web-based connectivity portal solution for laboratories and physicians. It serves physicians, geneticists, hospitals, clinics, and correctional and other health facilities. The company was founded in 1981 and is headquartered in Elmwood Park, New Jersey.

3,338 Employees
Last Reported Date: 01/13/14
Founded in 1981

bio-reference labs inc (BRLI) Top Compensated Officers

Founder, Chairman, Chief Executive Officer, P...
Total Annual Compensation: $1.2M
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $449.2K
Chief Operating Officer, Executive Vice Presi...
Total Annual Compensation: $449.9K
Compensation as of Fiscal Year 2013.

bio-reference labs inc (BRLI) Key Developments

Bio-Reference Laboratories Inc. Announces Unaudited Earnings Results for the Second Quarter and Six Months Ended April 30, 2014

Bio-Reference Laboratories Inc. announced unaudited earnings results for the second quarter and six months ended April 30, 2014. For the quarter, the company reported net revenue was $201,366,000 against $176,452,000 a year ago. Operating income was $18,879,000 compared to $20,709,000 a year ago. Income before taxes was $18,238,000 compared to $20,195,000 a year ago. Net income was $10,273,000 compared to $11,338,000 a year ago. Income per diluted share was $0.37 compared with the prior-year period's $0.41 per diluted share. For the six months, the company reported net revenue was $382,635,000 against $337,709,000 a year ago. Operating income was $24,760,000 compared to $36,468,000 a year ago. Income before taxes was $23,494,000 compared to $35,569,000 a year ago. Net income was $13,227,000 compared to $20,003,000 a year ago. Income per diluted share was $0.47 compared with the prior-year period's $0.72 per diluted share. The company estimates that the adverse effects of weather during the first six months of fiscal year 2014 resulted in approximately a $0.10 reduction in EPS. Cash flow from operations was a negative $188, compared to a positive $12,832 in the prior year same period, although significantly better than aggregate net negative cash flow from operations reported over the previous two reported quarters.

Bio-Reference Laboratories, Inc. Adopts Amended and Restated Bylaws

On June 3, 2014, the Board of Directors of Bio-Reference Laboratories Inc. adopted Amended and Restated Bylaws. The Amended and Restated Bylaws became effective immediately. The summary of the provisions of the Amended and Restated Bylaws that differ from the prior Bylaws. Such summary is not intended to be complete and is qualified in its entirety by reference to the full text of the Amended and Restated Bylaws.

Bio-Reference Laboratories Inc. to Report Q2, 2014 Results on Jun 05, 2014

Bio-Reference Laboratories Inc. announced that they will report Q2, 2014 results on Jun 05, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BRLI:US $30.97 USD +0.22

BRLI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alliance HealthCare Services Inc $29.30 USD -0.49
Genomic Health Inc $26.51 USD -0.14
Myriad Genetics Inc $37.58 USD +0.23
RadNet Inc $5.43 USD -0.27
Sequenom Inc $3.68 USD 0.00
View Industry Companies
 

Industry Analysis

BRLI

Industry Average

Valuation BRLI Industry Range
Price/Earnings 21.9x
Price/Sales 1.1x
Price/Book 3.0x
Price/Cash Flow 13.8x
TEV/Sales 1.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIO-REFERENCE LABS INC, please visit www.bioreference.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.